AAAna Beatriz Machado de Almeida

Ana Beatriz Machado de Almeida

*This is an algorithmically generated author record based on publicly available information.

Ana Beatriz Machado de Almeida has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the treatment of patients with paroxysmal nocturnal hemoglobinuria in Brazil: disparities in access and treatment persistence

    by Rodolfo Delfini Cançado, Paula de Melo Campos, Diego Kashiura, Felipe Thies, Erica Ferreira, Ana Beatriz Machado de Almeida, Lays Paulino Leonel, Lucas Vieira Cortez, Nina Melo, Fabio Fedozzi, et al.

  • Open Access

    Demographics, treatment patterns, and healthcare resource utilization in Parkinson's disease: a real-world data study using a claims database

    by Alexandre Battaglini Chehin, Luciana Rahal Abrahão, Marcos Augusto Mira Fuga, Ana Beatriz Machado de Almeida, Angelica Carreira dos Santos, Jacy Bezerra Parmera

    Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with substantial disability, morbidity, and mortality. Timely diagnosis and treatment are essential to mitigate its impact. Despite its burden, real-world data on PD in Brazil remain limited. To describe the demographic and clinical profile of individuals with PD treated in the Brazilian public healthcare system and to evaluate patterns of treatment and healthcare resource utilization (HCRU). The present observational, retrospective, longitudinal study analyzed data from the Brazilian public healthcare system (Sistema Único de Saúde, SUS, in Portuguese) between January 2013 and December 2022. Patients aged ≥ 20 years with at least 2 core procedures coded for PD (ICD-10 G20) were included. Inpatient and outpatient datasets were analyzed separately. A total of 53,674 PD patients were identified. The mean age at diagnosis was 65.4 years, with a slight male predominance (53.0%). Most patients (47.0%) had more than 6 outpatient visits, and 44.4% had 1 or 2 hospitalizations. The most frequent procedures were PD treatment (inpatient) and physical therapy (outpatient). The most used medications were pramipexole (45.6%), amantadine (26.0%), and entacapone (17.1%). The present study provides valuable insights into the demographic and clinical profile of PD patients in Brazil, highlighting frequent procedures and treatment patterns. A key limitation is the non-capture of basic PD medications, such as levodopa, which are often dispensed outside the analyzed datasets. These findings underscore the need for improved data integration and access to comprehensive PD care within the public health system.

  • Open Access

    Healthcare Resource Utilization and Direct Costs of Chronic Myeloid Leukemia in the Brazilian Public Health System

    by Johnny Wallef Leite Martins, Diogo Noin de Oliveira, André Henrique Ornelas de Oliveira, Ana Beatriz Machado de Almeida, Gustavo Pires Matheus, Alessandro Bigoni

    Objectives: This study evaluated healthcare resource utilization (HCRU), direct costs, and cost avoidance associated with chronic myeloid leukemia (CML) treatment within Brazil’s public healthcare system (SUS). Methods: A retrospective observational analysis was conducted using data from Ambulatory (SIA) and Hospital (SIH) Information Systems. Adults (≥ 18 years) with at least one ICD‐10 C92.1 claim between January 2013 and December 2023 were included. Results: A total of 13,162 patients were analyzed, predominantly male (55.0%) with a median age of 51 years (IQR: 39–63) and an average follow‐up of 4.0 years. Most patients (90.8%) were in the chronic phase. On average, patients had 42.8 outpatient visits. Hospitalization occurred in 16.7% of patients, and 10.4% required intensive care unit (ICU) care. In the chronic phase, outpatient visits averaged 31.9 in line of therapy (LOT) 1 and 16.6 in LOT3. Hospitalization and ICU rates were highest in LOT3 (12.6% and 18.5%, respectively). Total direct costs were USD 30.02M for outpatient visits, USD 1.69M for procedures, and USD 13.38M for hospitalizations. Per‐patient outpatient costs ranged from USD 1060.76 in LOT1 to USD 2895.90 in LOT3; hospitalization costs ranged from USD 2888.81 in LOT1 to USD 11,847.06 in LOT3. Cost avoidance analysis revealed that patients undergoing hematopoietic stem cell transplantation (HSCT) incurred significantly higher annual costs (USD 17,198) compared to those who did not (USD 844). Patients who experienced blast crises had annual costs of USD 3363 versus USD 913 for those without. Therapeutic failure was associated with increased costs (USD 1458 vs. USD 924 per year), highlighting the financial impact of disease progression and treatment resistance. Conclusions: CML treatment within SUS imposes a substantial economic burden, particularly in advanced LOTs. Later LOTs and disease progression are associated with increased hospitalizations, ICU admissions, and higher costs. These findings underscore the importance of early and sustained disease control to reduce healthcare expenditures and improve patient outcomes.

  • Open Access

    Jornada do Paciente com Mieloma Múltiplo no Brasil: Um Estudo Descritivo

    by Ana Carolina Gomes dos Santos, Ana Beatriz Machado de Almeida, Fernanda Cristina Santos Simão, Nina Melo, Janaína Rosenburg Gioseffi, Fábio Augusto Fedozzi, Catherine Moura Fonseca Pinto, Nelson Hamerschlak

    OBJETIVO: Este estudo analisou dados sociodemográficos e o tratamento de pacientes portadores de mieloma múltiplo no Brasil, identificando impactos nos sistemas de saúde. MÉTODOS: Estudo descritivo por meio de questionário autopreenchido, enviado entre outubro de 2021 e janeiro de 2023 a pacientes cadastrados na Associação Brasileira de Linfoma e Leucemia (Abrale). RESULTADOS: Participaram 164 pacientes, dos quais 133 (81%) tinham sintomas antes do diagnóstico. A maioria (117; 71%) passou por duas ou mais consultas antes do hematologista. O tempo médio para diagnóstico foi maior no sistema público (178 dias) que no privado (128 dias), e 38% relataram dificuldades de acesso. O diagnóstico e tratamento impactaram a rotina de 138 (84%) pacientes. CONCLUSÃO: Os resultados reforçam a importância de mapear obstáculos para discutir melhorias no tratamento e garantir atendimento adequado a todos.

  • Open Access

    Uso de linkage para análise de completude e concordância de óbitos por sífilis congênita na Região Metropolitana de São Paulo, 2010-2017: estudo descritivo

    by Ana Beatriz Machado de Almeida, Zilda Pereira da Silva

    Resumo Objetivo: Avaliar a completude e concordância dos óbitos infantis por sífilis congênita na Região Metropolitana de São Paulo, Brasil, no período 2010-2017. Métodos: Estudo descritivo, baseado na vinculação do Sistema de Informações sobre Mortalidade (SIM) com o Sistema de Informações sobre Nascidos Vivos (Sinasc). Foram considerados os óbitos com menção de sífilis congênita nas causas múltiplas de morte. Analisou-se a completude de 11 variáveis do SIM; adotou-se o Sinasc como referência. Para análise da concordância, utilizou-se o índice Kappa. Resultados: Registraram-se 134 óbitos por sífilis congênita; destes, 132 foram vinculados, sendo 67 como causa básica e 65 ao se considerar causas múltiplas de óbito, indicando subestimação da mortalidade. Após linkage, houve aumento de 2 para 10 variáveis com preenchimento excelente. Conclusão: A vinculação do SIM com dados do Sinasc melhorou sua completude. Identificou-se subestimação da magnitude da mortalidade por sífilis congênita, e o uso das causas múltiplas melhorou sua mensuração.